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 What’s already known about this topic? Cell-free DNA testing in the maternal 
blood is a highly efficient method of screening for common fetal trisomies. 
 
 What does this study add? In high-risk patients after first-trimester combined 
screening, a policy of selecting a subgroup for invasive testing and another for 
cfDNA testing ensures that most trisomies are detected and allows to diagnose 
more than 60% of abnormalities that are not currently investigated by the cfDNA 
test. 
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Abstract 
Objective: To investigate a strategy for clinical implementation of cfDNA testing in 
high-risk pregnancies after first-trimester combined screening. 
Methods: In 259 singleton pregnancies undergoing invasive testing after first 
trimester combined screening, a maternal blood sample was sent to the laboratory 
Natera for cfDNA testing using a SNP-based methodology. 
Results: The cfDNA test provided a result in 249 (96.1%) pregnancies and, among 
these, identified as being at high risk 35 of 36 cases of trisomy 21, 13 of 13 with 
trisomy 18, 5 of 5 with trisomy 13 and 3 of 4 with sex chromosome aneuploidies. A 
policy of performing an invasive test in women with a combined risk of >1 in 10 or NT 
>4 mm and offering cfDNA testing to the remaining cases, would detect all cases of 
trisomy 21, 18 or 13, 80% of sex aneuploidies and 62.5% of other defects, and would 
avoid an invasive procedure in 82.4% of euploid fetuses.  
Conclusion: In high-risk pregnancies after combined screening, a policy of selecting a 
subgroup for invasive testing and another for cfDNA testing would substantially 
reduce the number of invasive procedures and retain the ability to diagnose most of 
the observed aneuploidies. 
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Introduction 
One of the most widely used methods of screening for trisomy 21, 18 and 13 is 
based on the combination of maternal age, sonographic measurement of fetal nuchal 
translucency (NT) thickness and maternal serum free ß-hCG and PAPP-A at 11-13 
weeks’ gestation. It has been demonstrated that the combined test can identify about 
90% of fetuses with trisomy 21 and approximately 95% of those with trisomy 18 and 
13, for an overall invasive testing rate of 3-5%1.  
Recent studies have shown that cell-free DNA (cfDNA) testing in the maternal blood 
can detect more than 99% of fetuses with trisomy 21, 96% of trisomy 18, 92% of 
trisomy 13 and 90% of monosomy X, for an overall false positive rate of about 
0.5%2,3. In the screen positive group of combined testing, the use of cfDNA analysis 
has the main objectives of firstly, retain the ability to diagnose the vast majority of the 
chromosomal defects included in this population and secondly, substantially reduce 
the overall invasive testing rate of first trimester combined screening by re-assessing 
the risk for common trisomies in pregnancies with a screen positive result. In this 
respect, the components of combined testing, such as the risk score and NT 
thickness, should be taken into account to identify those patients that should be 
offered a diagnostic invasive procedure independently from the results of the cfDNA 
test. In addition, first trimester combined screening incidentally detects chromosomal 
abnormalities which are different from those targeted by the test and that cannot 
currently be identified by cfDNA analysis4.  
The objective of this study was to examine the impact of cfDNA testing on the 
diagnosis of chromosomal defects in pregnancies with a screen positive result from 
the combined test and to assess the clinical value of using the combined risk score 
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and the measurement of NT thickness to select a subgroup that should be offered 
invasive testing and another that could have the cfDNA test. 
 
Methods 
This was a multicentre study involving four fetal medicine centres in Italy (Mangiagalli 
Hospital in Milan, Di Venere and Sarcone Hospitals in Bari, Palagi Hospital in 
Florence). During a 10 month period (March to December 2014), we examined 259 
consecutive singleton pregnancies attending our centres for invasive testing because 
the estimated risk for trisomies 21, 18 or 13 after first-trimester combined screening 
was >1 in 250, which is the recommended risk cut-off for invasive testing according 
to local guidelines. Screening was undertaken at the participating centres or, in a 
minority of cases, women were referred from other hospitals because of a high risk 
after combined testing, which was based on the combination of maternal age, fetal 
NT thickness, fetal heart rate and maternal serum free ß-hCG and PAPP-A at 11-13 
weeks’ gestation. The ultrasound scans were carried out by trained sonographers 
accredited by the Fetal Medicine Foundation (FMF London, UK – 
www.fetalmedicine.org). In all cases fetal karyotyping was carried out by chorionic 
villous sampling or amniocentesis. Additional genetic testing, such as microarray-
CGH analysis and others, was carried out in selected cases based on the clinician’s 
decision, including NT thickness ≥ 3.5 mm and/or evidence of a major structural 
defect on ultrasound.  
In all cases, before invasive testing, a transabdominal ultrasound examination was 
carried out (RAB 4-8 probe, Voluson E8 Expert, GE Medical Systems, Milwaukee, 
WI, USA) and a maternal venous blood sample (20mL in Streck cell-free DNA 
BCTTM tubes) was obtained and shipped overnight to the laboratory to the USA for 
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cfDNA testing (Natera Inc., San Carlos, CA). The data provided to the laboratory 
were: patient unique identifier, maternal age, gestational age, racial origin and date of 
blood collection.  
In the laboratory, cfDNA was amplified using a massively multiplexed PCR 
methodology targeting 20,000 SNPs, sequenced, and analyzed with Bayesian-based 
algorithm to determine fetal ploidy status, as previously described5. The algorithm 
analyses a number of quality control metrics to identify laboratory or sequencing 
failure, estimate the amount of total starting DNA, determine the fetal fraction, and 
calculate the extent to which the measured cfDNA data fit expected case-specific 
distributions. In this study, a determination of the ploidy state of the fetus was not 
made if the fetal fraction was <4.0%, if the amount of input DNA was below 1500 
genome equivalents, or if off-allele contamination was >0.2%. Maternal genotypic 
information was incorporated into the analysis as previously described6. Results were 
provided in the form of the probability for a copy number of the five chromosomes 
(21, 18, 13, X and Y) interrogated in each sample, along with a sample-specific 
calculated accuracy for each chromosome. The risk cut-off used to define the screen 
positive group with the algorithm was >1 in 100. The results from invasive testing and 
cfDNA analysis were exchanged between the participating centers and the laboratory 
only upon study closure. The study was approved by the Institutional Review Board 
of Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy 
(reference n. 124, approved on 22nd January 2014). 
 
Statistical analysis 
The data were explored and analysed using the statistical software SPSS 12.0 
(Chicago, IL, USA) and Excel for Windows 2000 (Microsoft Corp., Redmond, WA, 
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USA). Fisher’s exact test was used to assess the differences in frequency distribution 
of categorical variables. 
 
Results 
The median maternal age of the study population was 36 (range 20-46) years, 
median fetal crown-rump length was 63.0 (range 45-84) mm and median NT 
thickness was 2.7 (range 1.0-12.7) mm. Invasive testing demonstrated chromosomal 
abnormalities in 71 (27.4%) of the 259 cases (Table 1). The abnormalities included 8 
(11.3%) that were not targeted by cfDNA testing and these are described in detail in 
Table 2. Microarray-CGH analysis was carried out in 32 cases and it was abnormal in 
3 fetuses (Table 2). 
On the total of 259 examined pregnancies, the cfDNA test provided a result in 249 
(96.1%) cases and, among these, correctly identified as being at high risk 35 of 36 
cases of trisomy 21, 13 of 13 with trisomy 18, 5 of 5 with trisomy 13 and 3 of 4 with 
sex chromosome aneuploidies (Table 1). The test also correctly identified as being 
low-risk all 184 euploid cases. In 10 cases the cfDNA test did not provide results 
because the fetal fraction was <4% in 8 and the sample failed internal quality control 
in 2. The no result rate was significantly higher in the group of aneuploidies, 
mosaicisms and structural re-arrangements compared to chromosomally normal 
fetuses (8.5% vs 2.1%, p<0.05). The no result group included 1 case of trisomy 21, 2 
of trisomy 18, 1 of trisomy 13, 1 of 47 XXX and 1 case with duplication in 
chromosome 8 (Table 1). 
The frequency distribution of different fetal karyotypes according to various cut-off 
values of combined test risk and NT thickness is shown in Figure 1. The group of 
fetuses with a risk > 1 in 10 and / or NT > 4 mm included the majority of the cases 
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with common trisomies and sex aneuploidies, more than 50% of fetuses with other 
defects and less than 20% of euploid pregnancies (Table 3). 
We examined the performance of a policy in which women with a risk from the 
combined test of >1 in 250 are subdivided into group A containing those with a risk of 
>1 in 10 or NT >4 mm and group B containing the remainder of cases (Figure 2). In 
group A, invasive testing is carried out and group B have cfDNA testing and 
subsequently invasive testing is carried out if the result is positive. Such policy would 
detect all cases of trisomy 21, 18 or 13, 80% of sex aneuploidies and 62.5% of cases 
with other chromosomal defects, and would avoid an invasive procedure in 82.4% of 
euploid fetuses. 
 
Discussion 
This study shows that in patients identified by the first-trimester combined test as 
being at high-risk of trisomies, a policy of selecting a subgroup for invasive testing 
and another for cfDNA testing can substantially reduce the number of invasive 
procedures, retain the ability to diagnose most trisomies and also diagnose more 
than 60% of abnormalities that are not currently detectable by the cfDNA test. 
Our data confirm previous evidence that sequencing of the SNP regions of cfDNA in 
the maternal blood is a highly efficient method of screening for common fetal 
trisomies5-7. Among cases with a result, a high risk score was provided in the vast 
majority of fetuses with trisomy 21, 18, 13 and monosomy X and all euploid fetuses 
were correctly classified as being at low risk. There were two false negative results, 
one each of trisomy 21 and monosomy X. In the case of trisomy 21 the fetal fraction 
was 4.4% and a recent study suggested, through statistical modelling, that the 
performance of cfDNA testing may be affected by the relative percentage of fetal 
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DNA in the maternal circulation, with a significantly lower detection rate for trisomy 21 
when the fetal fraction is below 6%8. Although this finding could partially explain our 
false negative result, further clinical studies are required to assess the relationship 
between the fetal fraction and the performance of cfDNA testing. The false negative 
case of monosomy X could be explained by the presence of a feto-placental 
mosaicism with an under-represented monosomic cell line in the cytotrophoblast, 
which is the source of cfDNA. The frequent occurrence of feto-placental mosaicism in 
cases with monosomy X could also explain the lower reported detection rate of 
cfDNA testing for this abnormality compared to the detection rate for trisomy 212. 
Analysis of cfDNA in the maternal blood did not provide a result in about 4% of the 
samples and this was mostly due to a low fetal fraction. A previous study showed that 
a repeated maternal blood sample would produce a result in about 60% of these 
cases9. However, our data confirm emerging evidence that the no result rate may be 
higher in fetuses with aneuploidies compared to those with normal karyotype3,7. 
Therefore, the importance of a low fetal fraction in re-assessing the risk for common 
trisomies after combined testing should be evaluated in large prospective clinical 
studies. 
It has been previously reported that the screen positive group of combined testing 
includes cases with abnormalities which were not initially targeted and that are 
incidentally detected, such as other trisomies, sex aneuploidies, deletions, 
duplications, mosaicisms and others4, and these defects accounted for about 10% of 
all aneuploidies in our study. Two recent studies analysed data on microarray-CGH 
results in a large number of pregnancies undergoing prenatal invasive testing for a 
variety of reasons, such as maternal age > 35 years, high risk from combined testing 
or second trimester serum screening, maternal request and others10,11. In the group 
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of pregnancies with a high risk from aneuploidy screening, the authors reported an 
overall incidence of copy number variations with known clinical significance or 
potential clinical significance of about 1%, which is similar to what was observed in 
our population (Table 2). However, we cannot exclude that some sub-chromosomal 
defects may have been missed because we performed microarray-CGH analysis only 
in 12% of cases in our cohort. There is some evidence that cfDNA testing can identify 
a proportion of fetuses with sub-chromosomal abnormalities12. However, there are 
insufficient data on reliable estimates of the detection rate and false positive rate of 
cfDNA testing for each of these defects in the general obstetric population. 
Therefore, in order to reduce the overall invasive testing rate of combined screening 
by using cfDNA analysis, it is inevitable that a proportion of abnormalities different 
from trisomy 21, 18 and 13 will not be diagnosed. 
In this study, the incidence of aneuploidies in fetuses with a combined risk > 1 in 10 
and NT > 4 mm was very high and a recent large study reported that this population 
includes only about 0.7% of the total of euploid fetuses4. Therefore, a policy of 
offering direct access to a diagnostic procedure in these cases would have a small 
impact on the overall invasive testing rate. In addition, it is well established that 
fetuses with high NT and a normal karyotype should undergo additional genetic 
testing that require chorionic villi or amniotic fluid samples13-14. 
The prevalence of common trisomies in our cohort was higher than what would have 
been expected in the screen-positive group of combined testing on the general 
obstetric population15 and this may be due to the fact that a minority of patients were 
referred from other centres, with a trend towards referral of very high-risk cases. Our 
results are unlikely to change significantly if a contingent strategy is applied to a 
screen-positive population with a relatively lower proportion of cases with common 
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trisomies and a higher number of non-trisomic fetuses, but larger clinical studies 
would be required to confirm our findings. 
Pregnancies with a risk from the combined test of < 1 in 250 were not examined as 
per our study design. It has been shown that this group includes about 10% of 
fetuses with trisomy 21 and a proportion of euploid fetuses which increases with 
decreasing combined risk cut-offs15. A recent study showed that there was no 
difference in the performance of cfDNA analysis by the SNPs method between high 
and low risk pregnancies7. Therefore, extending the use of cfDNA testing to lower 
risk categories, with the main objective of increasing the detection rate for common 
trisomies, will depend upon local health policies and economic resources necessary 
to offer the test to larger proportions of the obstetric population.  
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Figure legends 
 
Figure 1. Frequency distribution of different fetal karyotypes according to various cut-offs of 
combined risk (a) and NT thickness (b).      
    Euploid;     Trisomy 21;      Trisomy 18/13;     Sex aneuplodies;     Other defects   
 
Figure 2. Flow chart illustrating the contingent strategy of offering direct access to invasive 
testing if the risk from combined screening is > 1 in 10 and/or NT thickness is > 4.0 mm and 
re-assessing the risk for common trisomies by cfDNA testing in the lower risk group. 
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Table 1. Results from cfDNA testing according to fetal karyotype. 
 
 
 
Fetal karyotype n Cell free DNA test 
  No result Result Screen +ve Screen -ve 
Euploid 188 4 (2.1) 184 - 184 (100) 
Trisomy 21 37 1 (2.7) 36 35 (97.2) 1 (2.8) 
Trisomy 18 15 2 (13.3) 13 13 (100) - 
Trisomy 13 6 1 (16.7) 5 5 (100) - 
Monosomy X 3 0 (0.0) 3 2 (66.7) 1 (33.3) 
47,XXX or 47,XXY 2 1 (50.0) 1 1 (100) - 
Other 8 1 (12.5) 7 - 7 (100) 
Total 259 10 (3.9) 249 56 (22.5) 193 (77.5) 
 
Other = one case each of trisomy 4, trisomy 22, deletions in chromosomes 2, 4, 16, duplication in 
chromosome 8, Beckwith-Wiedemann syndrome, mosaicism 45X0/46XY 
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Table 2. Details on karyotype and microarray-CGH results in the 8 cases with chromosomal defects that were not targeted by cfDNA 1 
testing. 2 
 3 
Sample Standard karyotype Microarray-CGH Details 
CVS 47,XX+4 Not performed Homogeneous form 
CVS 47,XX+22  Not performed Homogeneous form 
Amnio 46,XY arr[hg19]2p16.3(50,892,877-51,083,440)x1 Deletion of the region 2p16.3 (size 190 Kb) 
CVS 46,XY,del(4)(q?) arr[hg19]4q13.1q24(64,247,237-102,510.250)x1dn Deletion of the region 4q13.1q24 (size 38 Mb) 
CVS  46,XY arr[hg19]16p11.2(29,673,984-30,190,539)x1 Deletion of the region 16p11.2 (size 516 Mb) 
CVS  46,XX arr[hg19]8p23.1(8,130,660-11,805,931)x3mat    Duplication of the region 8p23.1 (size 3.7 Mb) 
CVS 46,XY  Not performed Beckwith-Wiedemann (imprinting)  
CVS Mos45,X0/46,XY Not performed Mos45,X(10)/46,XY(36) 
 4 
CVS = chorionic villous sampling; Amnio = amniocentesis5 
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Table 3. Frequency distribution of cases with a combined risk > 1 in 10 and NT > 4.0 mm in 6 
relation to fetal karyotype. 7 
 8 
Fetal karyotype n Screen +ve result from combined test  
  Risk >1 in 10 Fetal NT >4 mm Either 
Euploid 188 26 (13.8) 12 (6.4) 33 (17.6) 
Trisomy 21 37 33 (89.2) 25 (67.6) 35 (94.6) 
Trisomy 18 15 14 (93.3) 11 (73.3) 14 (93.3) 
Trisomy 13 6 5 (83.3) 5 (83.3) 5 (83.3) 
Monosomy X 3 2 (66.7) 3 (100) 3 (100) 
47,XXX or 47,XXY 2 1 (50.0) 1 (50.0) 1 (50.0) 
Other 8 4 (50.0) 3 (37.5) 5* (62.5) 
Total 259 85 (32.8) 60 (23.2) 96 (37.1) 
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Other = one case each of trisomy 4 and trisomy 22, deletions in chromosomes 2, 4, 16, duplication in 10 
chromosomes 8, Beckwith-Wiedemann syndrome, mosaicism 45X0/46XY 11 
*Trisomy 4, deletion in chromosomes 16, duplication in chromosomes 8, Beckwith-Wiedemann syndrome, 12 
mosaicism 45X0/46XY 13 
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